Details for New Drug Application (NDA): 215602
✉ Email this page to a colleague
The generic ingredient in FLEQSUVY is baclofen. There are twenty-one drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the baclofen profile page.
Pharmacology for NDA: 215602
Mechanism of Action | GABA A Agonists GABA B Agonists |
Medical Subject Heading (MeSH) Categories for 215602
Suppliers and Packaging for NDA: 215602
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
FLEQSUVY | baclofen | SUSPENSION;ORAL | 215602 | NDA AUTHORIZED GENERIC | Wilshire Pharmaceuticals, Inc. | 52536-600 | 52536-600-11 | 1 BOTTLE in 1 CARTON (52536-600-11) / 120 mL in 1 BOTTLE |
FLEQSUVY | baclofen | SUSPENSION;ORAL | 215602 | NDA AUTHORIZED GENERIC | Wilshire Pharmaceuticals, Inc. | 52536-600 | 52536-600-12 | 1 BOTTLE in 1 CARTON (52536-600-12) / 300 mL in 1 BOTTLE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;ORAL | Strength | 25MG/5ML | ||||
Approval Date: | Feb 4, 2022 | TE: | AB | RLD: | Yes | ||||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 29, 2037 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 8, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | INDICATED FOR THE TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS |
Complete Access Available with Subscription